US Patent

US11707479 — Combination formulation of two antiviral compounds

Method of Use · Assigned to Gilead Sciences Inc · Expires 2034-01-30 · 8y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical composition combining Compound I and substantially crystalline sofosbuvir, along with methods of using this composition.

USPTO Abstract

Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1470`	—
`U-1470`	—

Patent Metadata

Patent number: US11707479
Jurisdiction: US
Classification: Method of Use
Expires: 2034-01-30
Drug substance claim: No
Drug product claim: Yes
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.